Literature DB >> 6097163

Inhibition of human cytomegalovirus replication by 9-(1,3-dihydroxy-2-propoxymethyl)guanine alone and in combination with human interferons.

L Rasmussen, P T Chen, J G Mullenax, T C Merigan.   

Abstract

The inhibitory action of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on the replication of human cytomegalovirus was studied. Three laboratory strains (AD-169, Towne, and Davis) and three early passage (less than 10) clinical isolates were all inhibited in yield inhibition assays. In cultures infected with AD-169, virus yields could be inhibited if the drug was added as late as 3 days after the replication cycle had begun. The effects of the drug were fully reversible during the first 4 days of the viral replication cycle. Viral infectivity and viral DNA synthesis were reduced more than viral protein synthesis. Synergistic antiviral effects were observed with beta-cysteine, and to a lesser extent, with beta-serine recombinant interferons, but only over a narrow range of dose combinations.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6097163      PMCID: PMC179941          DOI: 10.1128/AAC.26.4.441

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine.

Authors:  G B Elion; P A Furman; J A Fyfe; P de Miranda; L Beauchamp; H J Schaeffer
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

2.  9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group.

Authors:  H J Schaeffer; L Beauchamp; P de Miranda; G B Elion; D J Bauer; P Collins
Journal:  Nature       Date:  1978-04-13       Impact factor: 49.962

Review 3.  Structure and expression of human IFN-alpha genes.

Authors:  C Weissmann; S Nagata; W Boll; M Fountoulakis; A Fujisawa; J I Fujisawa; J Haynes; K Henco; N Mantei; H Ragg; C Schein; J Schmid; G Shaw; M Streuli; H Taira; K Todokoro; U Weidle
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1982-09-24       Impact factor: 6.237

4.  Inhibition of human herpesviruses by combination of acyclovir and human leukocyte interferon.

Authors:  M J Levin; P L Leary
Journal:  Infect Immun       Date:  1981-06       Impact factor: 3.441

5.  A new nucleoside analog, 9-[[2-hydroxy-1-(hydroxymethyl)ethoxyl]methyl]guanine, highly active in vitro against herpes simplex virus types 1 and 2.

Authors:  K O Smith; K S Galloway; W L Kennell; K K Ogilvie; B K Radatus
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

6.  Effect of 9-(2-hydroxyethoxymethyl)guanine on viral-specific polypeptide synthesis in human cytomegalovirus-infected cells.

Authors:  E C Mar; P C Patel; E S Huang
Journal:  Am J Med       Date:  1982-07-20       Impact factor: 4.965

7.  Effects of acyclovir combined with other antiviral agents on human cytomegalovirus.

Authors:  S A Spector; M Tyndall; E Kelley
Journal:  Am J Med       Date:  1982-07-20       Impact factor: 4.965

8.  Antiviral treatment of chronic hepatitis B virus infection: pharmacokinetics and side effects of interferon and adenine arabinoside alone and in combination.

Authors:  S L Sacks; G H Scullard; R B Pollard; P B Gregory; W S Robinson; T C Merigan
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

9.  The human fibroblast and human immune interferon genes and their expression in homologous and heterologous cells.

Authors:  W Fiers; E Remaut; R Devos; H Cheroutre; R Contreras; D Gheysen; W Degrave; P Stanssens; J Tavernier; Y Taya; J Content
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1982-09-24       Impact factor: 6.237

10.  Virus-specific IgG and IgM antibodies in normal and immunocompromised subjects infected with cytomegalovirus.

Authors:  L Rasmussen; D Kelsall; R Nelson; W Carney; M Hirsch; D Winston; J Preiksaitis; T C Merigan
Journal:  J Infect Dis       Date:  1982-02       Impact factor: 5.226

View more
  6 in total

Review 1.  Infectious disease therapy in the 1990s. Where are we heading?

Authors:  M Rozenberg-Arska; M R Visser
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

2.  Rapid determination of human cytomegalovirus susceptibility to ganciclovir directly from clinical specimen primocultures.

Authors:  J M Pepin; F Simon; A Dussault; G Collin; M C Dazza; F Brun-Vezinet
Journal:  J Clin Microbiol       Date:  1992-11       Impact factor: 5.948

3.  Treatment of cytomegalovirus retinitis with DHPG in a patient with AIDS.

Authors:  J M Hooymans; H G Sprenger; J Weits
Journal:  Doc Ophthalmol       Date:  1987 Sep-Oct       Impact factor: 2.379

4.  Ocular toxicity of multiple intravitreal DHPG injections.

Authors:  M O Yoshizumi; D Lee; V Vinci; S Fajardo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

Review 5.  Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections.

Authors:  D Faulds; R C Heel
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

6.  Active cytomegalovirus particles in the eyes of an AIDS patient being treated with 9-[2-hydroxy-1-(hydroxymethyl) ethoxymethyl] guanine (Ganciclovir).

Authors:  S A Teich; J Castle; A H Friedman; W Siroty; J Orellana; M Schmitterer
Journal:  Br J Ophthalmol       Date:  1988-04       Impact factor: 4.638

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.